Results 1 to 10 of about 257,584 (237)

Cyclophosphamide [PDF]

open access: greenBMJ, 1963
Cyclophosphamide, a recently-developed alkylating agent that may be administered orally, intramuscularly, and intravenously, was given to 135 patients with a wide variety of malignant diseases. Significant benefit was obtained in patients with lymphomas and leukemias as well as malignant melanoma, multiple myeloma, and carcinoma of the ovaries ...
G. Hamilton Fairley
  +7 more sources

Rapamycin Prevents cyclophosphamide-induced Over-activation of Primordial Follicle pool through PI3K/Akt/mTOR Signaling Pathway in vivo

open access: yesJournal of Ovarian Research, 2017
Background Primordial follicular depletion has thought to be a common adverse effect of chemotherapy especially for female of reproductive age. The study aimed to evaluate the protective effect of rapamycin on the primordial follicles and its potential ...
Linyan Zhou   +6 more
doaj   +2 more sources

Cyclophosphamide and the kidney [PDF]

open access: bronzeCancer, 1974
The effect of cyclophosphamide on renal function was studied in 17 normally hydrated patients with cancer. No nephrotoxic effects were observed. High-dose cyclophosphamide (⩾50 mg/kg body weight) did, however, impair water excretion as manifested by weight gain, hyponatremia, and inappropriately concentrated urine.
Ralph A. DeFronzo   +4 more
openalex   +3 more sources

Fish oil enhanced the efficacy of low-dose cyclophosphamide regimen for proliferative lupus nephritis: a randomized controlled double-blind trial

open access: yesFood & Nutrition Research, 2021
Background: Lupus nephritis (LN) is one of the most severe organ that damages the systemic lupus erythematosus (SLE). Cyclophosphamide is one of the main drugs used in the treatment of LN.
Chi Zhang   +3 more
doaj   +1 more source

Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis.

open access: yesNew England Journal of Medicine, 2023
BACKGROUND In patients undergoing allogeneic hematopoietic stem-cell transplantation (HSCT), a calcineurin inhibitor plus methotrexate has been a standard prophylaxis against graft-versus-host disease (GVHD).
J. Bolaños-Meade   +29 more
semanticscholar   +1 more source

Rituximab or Cyclophosphamide in the Treatment of Membranous Nephropathy: The RI-CYCLO Randomized Trial.

open access: yesJournal of the American Society of Nephrology, 2021
BACKGROUND A cyclic corticosteroid-cyclophosphamide regimen is the first-line therapy for membranous nephropathy. Compared with this regimen, rituximab therapy might have a more favorable safety profile, but a head-to-head comparison is lacking ...
F. Scolari   +18 more
semanticscholar   +1 more source

Cytochrome P450 Oxidoreductase Influences CYP2B6 Activity in Cyclophosphamide Bioactivation. [PDF]

open access: yesPLoS ONE, 2015
Cyclophosphamide is commonly used as an important component in conditioning prior to hematopoietic stem cell transplantation, a curative treatment for several hematological diseases.
Ibrahim El-Serafi   +4 more
doaj   +1 more source

Pharmacokinetics and Pharmacogenetics of Cyclophosphamide in a Neonate and Infant Childhood Cancer Patient Population

open access: yesPharmaceuticals, 2021
Infants and young children represent an important but much understudied childhood cancer patient population. The pharmacokinetics and pharmacogenetics of the widely used anticancer prodrug cyclophosphamide were investigated in children
Shelby Barnett   +6 more
doaj   +1 more source

The therapeutic effects of curcumin and capsaicin against cyclophosphamide side effects on the uterus in rats [PDF]

open access: yesActa Cirúrgica Brasileira, 2018
Purpose: To evaluate the impact of systemic cyclophosphamide treatment on the rat uterus and investigate the potential therapeutic effects of natural antioxidant preparations curcumin and capsaicin against cyclophosphamide side effects.
Ercan Yilmaz   +5 more
doaj   +1 more source

Home - About - Disclaimer - Privacy